Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 19/20 | 0.82 |
| ▸ | FNTB | P49356 | 19/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.82 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16792274 | 0.90 | FNTA (1.00) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL18151964 | 0.89 | FNTA (0.80) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792214 | 0.87 | FNTA (0.77) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL5756967 | 0.86 | GRIA4 (0.62) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16798046 | 0.84 | FNTA (0.82) | FNTAFNTBKMT2A | |
| SCHEMBL16792007 | 0.84 | FNTA (0.72) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792044 | 0.83 | FNTA (0.64) | FNTAFNTBKMT2A | |
| SCHEMBL16798062 | 0.82 | FNTA (0.69) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL16792140 | 0.81 | GRIA4 (0.64) | FNTAFNTBKMT2AGRIA4 | |
| SCHEMBL18151963 | 0.79 | FNTA (0.79) | FNTAFNTBKMT2AGRIA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2016-10-20 | — | — | US | disclosed |
| WO-2015089349-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-18 | — | — | WO | disclosed |
| WO-2015084721-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | TABACZYNSKI DAVID A (US) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160375041-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT AUTOIMMUNE DISORDERS | GGPS1, FDPS, COASY | FNTA 4/4885FNTB 15/4885KMT2A 4161/4885 |
| US-20160303146-A1 | INHIBITION OF ISOPRENOID BIOSYNTHETIC PATHWAYS TO TREAT NEUROINFLAMMATORY DISORDERS | GGPS1, FDPS, COASY | FNTA 4/4885FNTB 10/4885KMT2A 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.